US Hydrocephalus Shunts Market Size and Forecasts (2020 – 2030)

US Hydrocephalus Shunts Market Size and Forecasts (2020 – 2030), Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Hydrocephalus Valves, Hydrocephalus Catheters, Neuronavigation Systems, and Others), Type (Ventriculoperitoneal, Ventriculoatrial, Ventriculopleural, and Lumboperitoneal), Age Group (Pediatric and Adults), and End User (Hospitals, Ambulatory Surgical Centers, and Others)

Send Enquiry
Item ID: TIPRE00030116 Category: Tags: , ,

$2,100$3,500

Description

The US Hydrocephalus Shunts market size is expected to reach US$ 0.146 billion by 2030 from US$ 0.109 billion in 2022. The market is estimated to grow at a CAGR of 3.7% from 2022 to 2030.

Market Overview:

There are several treatment options available for hydrocephalus, including:

Shunt Systems: This is a common treatment where a shunt (a thin tube) is implanted to divert excess cerebrospinal fluid from the brain to another part of the body where it can be absorbed. There may have been advancements in shunt technology to improve their effectiveness and reduce complications.

Endoscopic Third Ventriculostomy (ETV): This is a surgical procedure where a small hole is made in the floor of the third ventricle of the brain to allow excess cerebrospinal fluid to flow out and be absorbed. ETV is used in certain cases of non-communicating hydrocephalus.

Ventriculostomy with Catheter: Another surgical option involves inserting a catheter directly into the brain’s ventricles to drain excess cerebrospinal fluid.

Intraventricular Endoscopy: Advances in minimally invasive techniques like endoscopy have allowed for more precise diagnosis and treatment of hydrocephalus.

Increasing Partnerships to Treat Hydrocephalus

US hydrocephalus shunts market companies are implementing strategies such as joint ventures and partnerships to extend their market shares. In 2020, Aesculap, Inc., partnered with Christoph Miethke GmbH & Co. KG (MIETHKE), and together they announced the launch of the M.blue hydrocephalus valve in the US. Its unique gravity technology is integrated with a fixed differential pressure unit in a valve, enabling a simple, position-dependent adjustment of the opening pressure during the patient’s most active time. Many market players are focused on developing “smart shunts” that could provide an understanding of flow or volume rates over time. Several industry partners are also developing devices that use thermodilution to estimate flow through a distal catheter to diagnose shunt malfunction. Thus, the increasing number of partnerships to aid in smart functioning of hydrocephalus shunts would lead to new future trends in the US hydrocephalus shunts market.

Growing Research to Improve the Quality of Shunts

Researchers have been developing improved shunts materials to reduce the risk of blockages, infections, and other complications.

Antibacterial Coatings: Researchers have been investigating coatings for shunts that have antibacterial properties. These coatings can help reduce the risk of infection when the shunt is implanted.

Anti-Blockage Mechanisms: Some shunt designs incorporate features to prevent or mitigate blockages. For example, valves with anti-siphon mechanisms can help maintain proper flow and prevent over-drainage or blockages.

Magnetic Valve Adjustments: Some shunt systems use magnets to adjust valve settings non-invasively, reducing the need for repeated surgeries.

Biocompatible Materials: The use of biocompatible materials in shunt construction can minimize the risk of allergic reactions or other adverse responses from the body.

Remote Monitoring: Advancements in remote monitoring technology have allowed for tracking shunt performance and intracranial pressure, helping healthcare providers identify issues before they become severe.

Nanotechnology: Nanotechnology applications have been explored for creating shunt components that resist bacterial adhesion and improve the overall durability of the shunt.

For instance, in 2021, Penn State researchers have been actively working on a groundbreaking technology called HydroFix. This innovative surgical shunt system is specifically designed to address the numerous risks associated with existing shunt devices available in the market. Its primary aim is to offer a long-lasting treatment solution for patients with Normal Pressure Hydrocephalus (NPH). To advance this technology, the researchers established a startup called Cranial Devices Inc. They are currently in the process of seeking a license for the HydroFix technology from Penn State University.

Similarly, Rhaeos, Inc., a clinical-stage medical device company, is developing FlowSense, a patented technology and a noninvasive wireless, wearable skin patch. FlowSense is a wireless, noninvasive thermal flow sensor that is mounted on a patient’s neck overlying the shunt to detect the presence and magnitude of CSF. With FlowSense, shunt function can be monitored in clinics, in-patient settings, and emergency departments, thereby reducing unnecessary imaging, hospital length of stay, and readmission costs.

US Hydrocephalus Shunts Market: Segmental Overview

The US hydrocephalus shunts market growth is segmented into product, type, age group, and end-user. On the basis of product, the market is segmented into hydrocephalus valves, hydrocephalus catheters, neuronavigation systems, and others. The hydrocephalus valves is further segmented into adjustable pressure valves, and fix pressure valves. In terms of type, the US hydrocephalus shunts market is segmented into ventriculoperitoneal, ventriculoatrial, ventriculopleural, and lumboperitoneal. The ventriculoperitoneal segment led the market in 2022 and is expected to retain its dominance during the forecast period. A ventriculoperitoneal (VP) shunt reduces pressure exerted on the brain by fluid accumulation by diverting CSF from the brain’s ventricles into the peritoneal cavity, the slot in the abdomen near digestive organs. Ventriculoperitoneal (VP) shunts are among the most commonly used tools for treating hydrocephalus. According to a research paper published in the National Center for Biotechnology Information (NCBI), a VP shunt has a high impact in advanced neurosurgical patient care. VP shunt can be lifesaving for benign disorders.

The US hydrocephalus shunts market, by age group, is segmented into pediatric and adults. The pediatric segment led the market in 2022 and is expected to retain its dominance during the forecast period by 2030. Hydrocephalus is the most common cause of brain surgery in children. A prenatal sonogram or MRI scan is recommended to identify hydrocephalus in a growing fetus. Infants generally show signs of progressive macrocephaly, whereas children older than 2 years show signs and symptoms of intracranial hypertension. Pediatric hydrocephalus can be dangerous if left untreated. Nevertheless, with early diagnosis and treatment, children often lead regular and healthy lives. According to the Hydrocephalus Association, 1–2 of every 1,000 babies have hydrocephalus in the US.

The US hydrocephalus shunts market, by end user, is segmented into hospitals, ambulatory surgical centers, others. The hospitals segment led the market in 2022 and is expected to retain its dominance during the forecast period by 2030. Hospitals provide healthcare to people through complicated but specialized scientific equipment. These facilities are classified into general, specialty, or government organizations. Hospitals serve a significant role by providing medical services to patient populations suffering from various diseases. The growth of the US hydrocephalus shunt market for the hospitals segment is attributed to an increase in the number of neurological surgeries, and a surge in demand for valves and neuronavigation systems in these facilities to treat the condition. Additionally, an increasing number of hospitals providing hydrocephalus surgeries in developed and developing countries is expected to boost the market growth in the future.

US Hydrocephalus Shunts Market: Key Players

B. Braun SE, Sophysa SA, Integra LifeSciences Holdings Corp, KANEKA MEDIX CORP, Medtronic Plc, Natus Medical Inc, Anuncia Inc, Desu Medical are among the leading companies operating in the US hydrocephalus shunts market.

A few of the key primary and secondary sources referred to while preparing the report on the US hydrocephalus shunts market are the World Health Organization (WHO), FDA (Food and Drug Administration), Hydrocephalus Association, National Institute of Neurological Disorders and Stroke (NINDS), University of California, Los Angeles Health Organization, National Center for Biotechnology Information, Children’s Health Orange County, amongst others.

Summary Info

Industry:

Number of pages:

Pricing options:

, ,

Publishing status:

Geographical coverage:

Year of Publication:

Surging Prevalence of Hydrocephalus to Drive US Hydrocephalus Shunts Market

According to our new research study on “US Hydrocephalus Shunts Market Forecast to 2030 – Country Analysis – by Product, Type, Age Group, End User,” the US Hydrocephalus Shunts market size is expected to reach US$ 0.146 billion by 2030 from US$ 0.109 billion in 2022. The market is estimated to grow at a CAGR of 3.7% from 2022 to 2030. The report highlights trends prevailing in the market, and drivers and restraints pertaining to the hydrocephalus shunts market.

Shunt, the surgical insertion of a drainage system, is the most common remedy for hydrocephalus. It drains extra cerebrospinal fluid from the brain and directs it to another body part, such as the abdomen, where it can be more easily absorbed. A shunt consists of a long and flexible tube with a valve that keeps fluid from the brain flowing in the right direction, at the proper rate.

Companies in the US hydrocephalus shunts market are introducing new advanced programmable valves, shunts based on the latest technologies, and anti-siphon devices, among others. In May 2021, researchers at the Pennsylvania State University established the startup named Cranial Devices Inc. HydroFix, an advanced surgical shunt system designed by this company, provides a durable solution for normal pressure hydrocephalus (NPH) patients, along with mitigating risks associated with currently existing shunts. They have also applied for a license for the HydroFix technology from the Pennsylvania State University. In 2020, researchers at MIT proposed a shunt design to overcome the clogging of hydrocephalus catheters by leveraging catheter geometry.

The hydrocephalus shunts market in the US is expected to grow from US$ 109.61 million in 2022 to US$ 146.24 million by 2030; it is expected to grow at a CAGR of 3.7% from 2022 to 2030. Hydrocephalus is a prime cause of morbidity worldwide, and it is estimated to affect ~1 million people in the US, with an approximate incidence of 0.2–0.8 per 1000 live births. According to the National Institute of Neurological Disorders and Stroke (NINDS), hydrocephalus is assumed to affect ~1–2 in every 1,000 children born in the US. As per the University of California, Los Angeles Health Organization Approximately 125,000 people in the U.S. are currently living with cerebrospinal fluid shunts.

The majority of hydrocephalus cases are often diagnosed before birth, at the time of delivery, or in early childhood. The US hospitals discharge approximately 69,000 patients annually with a primary diagnosis of hydrocephalus, of which half undergo placement of a new shunt. Over half of these admissions were classified as emergent or urgent, and the average cost OF treatment was found to be US$ 35,816 each. The article published by Ausmed entitled “Hydrocephalus and Shunts” estimates that 33,000 people have shunts placed every year in US CSF diversion surgery and shunt revision surgery account for nearly one-third of all neurosurgical procedures annually in the country.

According to a study titled “Management of Hydrocephalus in Children: Anatomic Imaging Appearances of CSF Shunts and Their Complications,” published in the American Journal of Roentgenology in 2020, hydrocephalus affects approximately 1–2% of the US population and results in 70,000 hospitalizations, with the placement of 18,000–33,000 CSF shunts, and annual healthcare expenditures in the country is approximately US$ 2 billion.

In July 2023, Anuncia Medical Inc. announced the successful commercial launch of the ReFlow Mini Flusher device in the US. The ReFlow System Mini is a platform developed to enhance the function of CSF management devices in operating rooms, intensive care units, and homes. The US FDA has cleared ReFlow System Mini and ReFlow Mini Flusher under 510(k) for use in the treatment of hydrocephalus as part of a CSF shunt system. In 2020, researchers at MIT proposed a design to overcome the clogging of hydrocephalus catheters by leveraging catheter geometry.

B. Braun SE, Sophysa SA, Integra LifeSciences Holdings Corp, KANEKA MEDIX CORP, Medtronic Plc, Natus Medical Inc, Anuncia Inc, Desu Medical are the leading companies in the US hydrocephalus shunts market.

– Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific frozen waffles market.
– Highlights key business priorities in order to assist companies to realign their business strategies.
– the key findings and recommendations highlight crucial progressive industry trends in Asia Pacific frozen waffles market, thereby allowing players across the value chain to develop effective long-term strategies.
– develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
– Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
– Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 Study Scope
1.2 Research Report Guidance
1.3 Market Segmentation
2. Key Takeaways
3. Research Methodology
3.1 Scope of the Study
3.2 Research Methodology
3.2.1 Data Collection:
3.2.2 Primary Interviews:
3.2.3 Hypothesis Formulation:
3.2.4 Macro-economic Factor Analysis:
3.2.5 Developing Base Number:
3.2.6 Data Triangulation:
3.2.7 Country Level Data:
4. South & Central America Collagen Peptides Market Landscape
4.1 Market Overview
4.2 Porter’s Five Forces Analysis
4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes
4.3 Expert Opinion
4.4 Ecosystem Analysis
4.4.1 Raw Materials
4.4.2 Production Process
4.4.3 End-Use Industries
5. South & Central America Collagen Peptides Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Wide Application Scope
5.1.2 Strategic Development Initiatives by Key Market Players
5.2 Market Restraints
5.2.1 Safety Concerns and Stringent Regulations Related to Consumption of Collagen Peptides
5.3 Market Opportunities
5.3.1 Surging Demand for Marine-Sourced Collagen Peptides
5.4 Future Trends
5.4.1 Escalating Trend of Using Collagen Peptides in Personal Care and Nutricosmetics
5.5 Impact Analysis of Drivers and Restraints
6. Collagen Peptides – South & Central America Market Analysis
6.1 South & Central America Collagen Peptides Market –Revenue and Forecast to 2030 (US$ Million)
7. South & Central America Collagen Peptides Market Analysis – By Source
7.1 Overview
7.2 South & Central America Collagen Peptides Market, By Source (2022 and 2030)
7.3 Bovine
7.3.1 Overview
7.3.2 Bovine: South & Central America Collagen Peptides Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Porcine
7.4.1 Overview
7.4.2 Porcine: South & Central America Collagen Peptides Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Poultry:
7.5.1 Overview
7.5.2 Poultry: South & Central America Collagen Peptides Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Marine:
7.6.1 Overview
7.6.2 Marine: South & Central America Collagen Peptides Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: South & Central America Collagen Peptides Market– Revenue and Forecast to 2030 (US$ Million)
8. South & Central America Collagen Peptides Market Analysis – By Form
8.1 Overview
8.2 South & Central America Collagen Peptides Market, By Form (2022 and 2030)
8.3 Dry
8.3.1 Overview
8.3.2 Dry: South & Central America Collagen Peptides Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Liquid
8.4.1 Overview
8.4.2 Liquid: South & Central America Collagen Peptides Market – Revenue and Forecast to 2030 (US$ Million)
9. South & Central America Collagen Peptides Market Analysis – By Application
9.1 Overview
9.2 South & Central America Collagen Peptides Market, By Application (2022 and 2030)
9.3 Food and Beverages
9.3.1 Overview
9.3.2 Food and Beverages: South & Central America Collagen Peptides Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Pharmaceuticals and Nutraceuticals
9.4.1 Overview
9.4.2 Pharmaceuticals and Nutraceuticals: South & Central America Collagen Peptides Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Personal Care
9.5.1 Overview
9.5.2 Personal Care: South & Central America Collagen Peptides Market – Revenue and Forecast to 2030 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: South & Central America Collagen Peptides Market – Revenue and Forecast to 2030 (US$ Million)
10. South & Central America Collagen Peptides Market – Country Analysis
10.1 South & Central America: Collagen Peptides Market
10.1.1 South & Central America: Collagen Peptides Market, by Key Country
10.1.1.1 Brazil: Collagen Peptides Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.1 Brazil: Collagen Peptides Market, By Source
10.1.1.1.2 Brazil: Collagen Peptides Market, By Form
10.1.1.1.3 Brazil: Collagen Peptides Market, by Application
10.1.1.2 Argentina: Collagen Peptides Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Argentina: Collagen Peptides Market, By Source
10.1.1.2.2 Argentina: Collagen Peptides Market, By Form
10.1.1.2.3 Argentina: Collagen Peptides Market, by Application
10.1.1.3 Rest of South & Central America: Collagen Peptides Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Rest of South & Central America: Collagen Peptides Market, By Source
10.1.1.3.2 Rest of South & Central America: Collagen Peptides Market, By Form
10.1.1.3.3 Rest of South & Central America: Collagen Peptides Market, by Application
11. Company Profiles
11.1 GELITA AG
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Rousselot BV
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Tessenderlo Group NV
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Lapi Gelatine SpA
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Darling Ingredients Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
12. Appendix
12.1 About
12.2 Word Index

LIST OF TABLES

Table 1. Organic Developments Done by Companies
Table 2. Glossary of Terms

LIST OF FIGURES

Figure 1. US Hydrocephalus Shunts Market Segmentation
Figure 2. US Hydrocephalus Shunts Market – Key Takeaways
Figure 3. US: PEST Analysis
Figure 4. Hydrocephalus Shunts Market: Key Industry Dynamics
Figure 5. US Hydrocephalus Shunts Market Impact Analysis of Drivers and Restraints
Figure 6. US Hydrocephalus Shunts Market – Revenue Forecast and Analysis – 2020–2030
Figure 7. US Hydrocephalus Shunts Market Revenue Share, by Product 2022 & 2030 (%)
Figure 8. Hydrocephalus Valves: US Hydrocephalus Shunts Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Adjustable Pressure Valves: US Hydrocephalus Shunts Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Fix Pressure Valves: US Hydrocephalus Shunts Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hydrocephalus Catheters: US Hydrocephalus Shunts Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Neuronavigation Systems: US Hydrocephalus Shunts Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: US Hydrocephalus Shunts Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. US Hydrocephalus Shunts Market Revenue Share, by Type 2022 & 2030 (%)
Figure 15. Ventriculoperitoneal: US Hydrocephalus Shunts Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Ventriculoatrial: US Hydrocephalus Shunts Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Ventriculopleural: US Hydrocephalus Shunts Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Lumboperitoneal: US Hydrocephalus Shunts Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. US Hydrocephalus Shunts Market Revenue Share, by Age Group 2022 & 2030 (%)
Figure 20. Pediatric: US Hydrocephalus Shunts Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Adults: US Hydrocephalus Shunts Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. US Hydrocephalus Shunts Market Revenue Share, by End User 2022 & 2030 (%)
Figure 23. Hospitals: US Hydrocephalus Shunts Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Ambulatory Surgical Centers: US Hydrocephalus Shunts Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Others: US Hydrocephalus Shunts Market – Revenue and Forecast to 2030 (US$ Million)

The List of Companies – US Hydrocephalus Shunts Market
– B. Braun SE
– Sophysa SA
– Integra LifeSciences Holdings Corp  
– KANEKA MEDIX CORP.
– Medtronic Plc  
– Natus Medical Inc  
– Anuncia Inc.  
– Desu Medical

Reviews

There are no reviews yet.

Be the first to review “US Hydrocephalus Shunts Market Size and Forecasts (2020 – 2030)”